Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control

MLA

Matt J. Walters, et al. “Abstract 5556: Combining Adenosine Receptor Inhibition with AB928 and Chemotherapy Results in Greater Immune Activation and Tumor Control.” Cancer Research, vol. 78, July 2018, p. 5556. EBSCOhost, https://doi.org/10.1158/1538-7445.am2018-5556.

APA

Matt J. Walters, Dillon H. Miles, Manmohan Reddy Leleti, Jay P. Powers, Eshan Sharif, Fang-Fang Yin, Tim Park, Dana Piovesan, Joanne Tan, Ulrike Schindler, Daniel DiRenzo, & Ferdie Soriano. (2018). Abstract 5556: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. Cancer Research, 78, 5556. https://doi.org/10.1158/1538-7445.am2018-5556

Chicago

Matt J. Walters, Dillon H. Miles, Manmohan Reddy Leleti, Jay P. Powers, Eshan Sharif, Fang-Fang Yin, Tim Park, et al. 2018. “Abstract 5556: Combining Adenosine Receptor Inhibition with AB928 and Chemotherapy Results in Greater Immune Activation and Tumor Control.” Cancer Research 78 (July): 5556. doi:10.1158/1538-7445.am2018-5556.